VEGFA and hepatocellular carcinoma: Recently, a VEGF inhibitor, sorafenib (Nexavar®, Bayer), significantly prolonged the time to tumor progression, increased overall survival in a placebo-controlled phase III study in HCC patients [6,7] and significantly increased the effectiveness of doxorubicin treatment in those suffering from advanced HCC [8].